The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.
Robert Z. Orlowski
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Cephalon; Johnson & Johnson; Millennium; Novartis; Onyx
Honoraria - Bristol-Myers Squibb; Celgene; Cephalon; Johnson & Johnson; Millennium; Novartis; Onyx
Liana Gercheva
Research Funding - Janssen Research & Development
Cathy Williams
Honoraria - MULTIPLE Myeloma Debate; Myeloma Evening Symposium; Young Haematologist Forum
Heather J Sutherland
Honoraria - Alexion Pharmaceuticals; Celgene; Janssen-Ortho; Novartis; Roche
Tadeusz Robak
Research Funding - Janssen Research & Development
Tamás Masszi
No relevant relationships to disclose
Vesselina Goranova-Marinova
No relevant relationships to disclose
Meletios A. Dimopoulos
Consultant or Advisory Role - Ortho Biotech
Honoraria - Ortho Biotech
James D. Cavenagh
Honoraria - Janssen Pharmaceuticals
Ivan Spicka
Consultant or Advisory Role - Janssen-Cilag (U)
Honoraria - Janssen-Cilag
Angelo Maiolino
No relevant relationships to disclose
Alexander Suvorov
No relevant relationships to disclose
Joan Blade
Honoraria - Janssen Research & Development
Research Funding - Janssen Research & Development
Olga S Samoilova
No relevant relationships to disclose
Helgi Van De Velde
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Rajesh Bandekar
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Britte Kranenburg
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Hong Xie
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Jean-Francois Rossi
Honoraria - Beta Innov